Trial record 1 of 1 for:
NCT01157351
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01157351 |
|
Recruitment Status :
Completed
First Posted : July 7, 2010
Results First Posted : December 4, 2014
Last Update Posted : April 24, 2015
|
Sponsor:
Janssen Scientific Affairs, LLC
Information provided by (Responsible Party):
Janssen Scientific Affairs, LLC
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been incarcerated.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Schizophrenia | Drug: paliperidone Drug: risperidone Drug: haloperidole Drug: perphenazine Drug: aripiprazole Drug: quetiapine Drug: paliperidone palmitate Drug: olanzapine | Phase 4 |
The primary objective of this study is to compare the efficacy of paliperidone palmitate with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been incarcerated. Protocol-defined treatment failure is defined as arrest, psychiatric hospitalization, increase in psychiatric services to prevent imminent hospitalization, discontinuation of antipsychotic treatment due to inadequate efficacy, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to safety or tolerability or completed suicide. Protocol was amended on March 15, 2011 to reflect changes in the inclusion/exclusion criteria as well as the study objectives. Patients will receive either paliperidone palmitate 78, 117, 156, or 234 mg monthly by injection for fifteen months OR oral aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, and risperidone at doses selected by the study doctor.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 450 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Prevention |
| Official Title: | A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated |
| Study Start Date : | May 2010 |
| Actual Primary Completion Date : | December 2013 |
| Actual Study Completion Date : | December 2013 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Schizophrenia
MedlinePlus related topics:
Schizophrenia
| Arm | Intervention/treatment |
|---|---|
|
Experimental: 001
paliperidone palmitate 78 117 156 or 234 mg monthly injection for 15 months
|
Drug: paliperidone palmitate
78, 117, 156, or 234 mg monthly injection for 15 months |
|
Active Comparator: 002
aripiprazole flexible dosing as prescribed by the study doctor for 15 months
|
Drug: aripiprazole
flexible dosing as prescribed by the study doctor for 15 months |
|
Active Comparator: 003
haloperidole flexible dosing as prescribed by the study doctor for 15 months
|
Drug: haloperidole
flexible dosing as prescribed by the study doctor for 15 months |
|
Active Comparator: 004
olanzapine flexible dosing as prescribed by the study doctor for 15 months
|
Drug: olanzapine
flexible dosing as prescribed by the study doctor for 15 months |
|
Active Comparator: 005
paliperidone flexible dosing as prescribed by the study doctor for 15 months
|
Drug: paliperidone
flexible dosing as prescribed by the study doctor for 15 months |
|
Active Comparator: 006
perphenazine flexible dosing as prescribed by the study doctor for 15 months
|
Drug: perphenazine
flexible dosing as prescribed by the study doctor for 15 months |
|
Active Comparator: 007
quetiapine flexible dosing as prescribed by the study doctor for 15 months
|
Drug: quetiapine
flexible dosing as prescribed by the study doctor for 15 months |
|
Active Comparator: 008
risperidone flexible dosing as prescribed by the study doctor for 15 months
|
Drug: risperidone
flexible dosing as prescribed by the study doctor for 15 months |
Primary Outcome Measures :
- Time to First Treatment Failure [ Time Frame: From date of randomization up to Month 15 ]Time to first treatment failure was the time from participant randomization to the first treatment failure, which was a composite endpoint consisting of any of the following events: arrest/incarceration, psychiatric hospitalization, discontinuation of antipsychotic treatment due to safety or tolerability, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to inadequate efficacy, increase in level of psychiatric services to prevent imminent psychiatric hospitalization, suicide. A Treatment Failure Event Monitoring Board (EMB), blinded to individual participant treatment assignment, determined the occurrence and date of the first treatment failure event.
- Percentage of Participants in Each Event Category of First Treatment Failure [ Time Frame: From date of randomization up to Month 15 ]First treatment failure was a composite endpoint consisting of any of the following events: arrest/incarceration, psychiatric hospitalization, discontinuation (D/C) of antipsychotic treatment due to safety or tolerability, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to inadequate efficacy, increase in level of psychiatric services to prevent imminent psychiatric hospitalization, suicide. A Treatment Failure Event Monitoring Board (EMB), blinded to individual participant treatment assignment, determined the occurrence and date of the first treatment failure event. Percentage of participants who experienced treatment failure due to any event and for each specific category of event were assessed.
Secondary Outcome Measures :
- Time to First Psychiatric Hospitalization or Arrest/Incarceration [ Time Frame: From date of randomization up to Month 15 ]A time to parameter looking only at 2 component events of treatment failure: arrest or incarceration, and psychiatric hospitalization. An arrest was defined as the taking of a participant into custody by legal authority, for any reason. Incarceration was defined as involuntary confinement by an officer of the law. Psychiatric hospitalization was an inpatient psychiatric hospitalization that occurred due to the participant's clinically significant worsening of symptoms of schizophrenia.
- Change From Baseline in Personal and Social Performance (PSP) Total Score During Overall Treatment Duration [ Time Frame: Baseline up to Month 15 ]The PSP score assesses the degree of difficulty a participant exhibit over a 1 month period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The investigators rate participants' degree of difficulty in each of the 4 domains using a 6-point Likert scale (from 0=absent to 5=very severe). The domain ratings were then transformed to PSP total score ranging from 1 to 100. Higher PSP total scores denote better functioning. A score between 71 and 100 represents normal to mild degree of dysfunction; a score between 31 and 70 represents varying degree of difficulty; and a score <=30 represents poor function that requires intensive supervision.
- Time to First Psychiatric Hospitalization [ Time Frame: From date of randomization up to Month 15 ]A time-to parameter looking only at 1 component event of treatment failure: psychiatric hospitalization. Time to first psychiatric hospitalization was admission date of the psychiatric hospitalization recorded in the "Assessment of Treatment Failure - Psychiatric Hospitalization."
- Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score During Overall Treatment Duration [ Time Frame: Baseline up to Month 15 ]The CGI-S rating scale was a 7-point global assessment of symptom severity with scores determined by clinician as follows: 1=Not ill, 2=Very Mild, 3= Mild, 4= Moderate, 5= Marked, 6= Severe, and 7= Extremely Severe. The higher the score the worse the illness.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Must be able to understand and sign the informed consent form approved by the Institutional Review Board (IRB)
- Must successfully answer all the questions on the Informed Consent quiz indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
- Have a current diagnosis of schizophrenia
- Taking no more than 1 oral antipsychotic on the day before randomization
- Have been placed into custody at least twice with one of them leading to incarceration within the 24 months previous to study start, with the last release occurring within the 90 days before the first day of screening
- in the opinion of the investigator, may benefit from a change in their prior antipsychotic treatment
- Have available a designated individual (eg, family member, case manager, significant other, probation/parole officer) who has knowledge of the patient and is generally aware of the patient's daily activities, and who agrees to let the study site personnel know of changes in the patients circumstances when the patient is not able to provide this information, ie, arrests, protocol-defined hospitalizations, emergency room visits, becoming homeless, etc.
- Have either an address or phone number where they can be reached, or be accessible to the designated individual
- Must agree to receive regular injections for 15 months if randomly assigned to the paliperidone palmitate treatment group, or continue with oral study medication treatment for 15 months if randomly assigned to the oral antipsychotic treatment group
- Women must be postmenopausal (for at least 2 years), surgically sterile (hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), abstinent, or if sexually active, be practicing a highly effective method of birth control
Exclusion Criteria:
- Allergies, hypersensitivity (anaphylaxis-type reaction), or intolerance to risperidone or paliperidone
- Actively abusing intravenous drugs within the past 3 months or have an opiate dependence disorder
- Have a positive urine drug screen test for barbiturates, cocaine, amphetamines, or opiates at screening
- Women who are pregnant or breast-feeding, or planning to become pregnant
- Have received injectable antipsychotic treatment within 2 injection cycles prior to screening
- Received treatment with clozapine within 3 months of screening
- Are at a high risk of violence in the next 15 months, in the opinion of the investigator
- who have a history of sex offenses including felony sex offenses, child molestation
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01157351
Locations
Show 56 study locations
Sponsors and Collaborators
Janssen Scientific Affairs, LLC
Investigators
| Study Director: | Janssen Scientific Affairs, LLC Clinical Trial | Janssen Scientific Affairs, LLC |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Janssen Scientific Affairs, LLC |
| ClinicalTrials.gov Identifier: | NCT01157351 |
| Other Study ID Numbers: |
CR015625 R092670SCH3006 ( Other Identifier: Janssen Scientific Affairs, LLC ) |
| First Posted: | July 7, 2010 Key Record Dates |
| Results First Posted: | December 4, 2014 |
| Last Update Posted: | April 24, 2015 |
| Last Verified: | April 2015 |
Keywords provided by Janssen Scientific Affairs, LLC:
|
Schizophrenia Risperidone Risperdal Paliperidone palmitate Aripiprazole |
Haloperidol Olanzapine Paliperidone Perphenazine Quetiapine |
Additional relevant MeSH terms:
|
Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Olanzapine Risperidone Aripiprazole Quetiapine Fumarate Paliperidone Palmitate Perphenazine Serotonin Antagonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Antipsychotic Agents |
Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Dopamine Antagonists Dopamine Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Antidepressive Agents Dopamine Agonists Serotonin 5-HT1 Receptor Agonists |